Annual EBITDA:
-$426.72M-$119.09M(-38.71%)Summary
- As of today, RXRX annual EBITDA is -$426.72 million, with the most recent change of -$119.09 million (-38.71%) on December 31, 2024.
- During the last 3 years, RXRX annual EBITDA has fallen by -$251.60 million (-143.67%).
- RXRX annual EBITDA is now -626.27% below its all-time high of -$58.76 million, reached on December 31, 2019.
Performance
RXRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$151.16M+$1.22M(+0.80%)Summary
- As of today, RXRX quarterly EBITDA is -$151.16 million, with the most recent change of +$1.22 million (+0.80%) on September 30, 2025.
- Over the past year, RXRX quarterly EBITDA has dropped by -$60.91 million (-67.48%).
- RXRX quarterly EBITDA is now -779.19% below its all-time high of -$17.19 million, reached on June 30, 2020.
Performance
RXRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$646.25M-$60.91M(-10.41%)Summary
- As of today, RXRX TTM EBITDA is -$646.25 million, with the most recent change of -$60.91 million (-10.41%) on September 30, 2025.
- Over the past year, RXRX TTM EBITDA has dropped by -$281.00 million (-76.93%).
- RXRX TTM EBITDA is now -3612.79% below its all-time high of -$17.41 million, reached on March 31, 2020.
Performance
RXRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RXRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -38.7% | -67.5% | -76.9% |
| 3Y3 Years | -143.7% | -162.5% | -173.1% |
| 5Y5 Years | -626.3% | -608.9% | - |
RXRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -143.7% | at low | -171.0% | +12.1% | -181.0% | at low |
| 5Y | 5-Year | -626.3% | at low | -419.8% | +12.1% | -856.0% | at low |
| All-Time | All-Time | -626.3% | at low | -779.2% | +12.1% | -3612.8% | at low |
RXRX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$151.16M(+0.8%) | -$646.25M(-10.4%) |
| Jun 2025 | - | -$152.38M(+11.4%) | -$585.34M(-11.4%) |
| Mar 2025 | - | -$172.04M(-0.8%) | -$525.51M(-18.8%) |
| Dec 2024 | -$426.72M(-38.7%) | -$170.67M(-89.1%) | -$442.41M(-21.1%) |
| Sep 2024 | - | -$90.25M(+2.5%) | -$365.25M(+0.5%) |
| Jun 2024 | - | -$92.54M(-4.1%) | -$366.95M(-5.3%) |
| Mar 2024 | - | -$88.94M(+4.9%) | -$348.57M(-7.7%) |
| Dec 2023 | -$307.63M(-35.1%) | -$93.51M(-1.7%) | -$323.78M(-13.2%) |
| Sep 2023 | - | -$91.95M(-24.0%) | -$286.05M(-13.6%) |
| Jun 2023 | - | -$74.17M(-15.6%) | -$251.70M(-4.5%) |
| Mar 2023 | - | -$64.15M(-15.0%) | -$240.93M(-4.8%) |
| Dec 2022 | -$227.66M | -$55.78M(+3.1%) | -$230.00M(+2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$57.59M(+9.2%) | -$236.60M(-6.2%) |
| Jun 2022 | - | -$63.41M(-19.2%) | -$222.83M(-12.5%) |
| Mar 2022 | - | -$53.21M(+14.7%) | -$198.02M(-13.9%) |
| Dec 2021 | -$175.12M(-114.3%) | -$62.38M(-42.3%) | -$173.89M(-55.9%) |
| Sep 2021 | - | -$43.83M(-13.5%) | -$111.51M(-25.3%) |
| Jun 2021 | - | -$38.60M(-32.7%) | -$89.00M(-31.7%) |
| Mar 2021 | - | -$29.08M(-36.4%) | -$67.60M(-20.9%) |
| Dec 2020 | -$81.70M(-39.1%) | - | - |
| Sep 2020 | - | -$21.32M(-24.0%) | -$55.92M(-61.6%) |
| Jun 2020 | - | -$17.19M(+1.2%) | -$34.60M(-98.8%) |
| Mar 2020 | - | -$17.41M | -$17.41M |
| Dec 2019 | -$58.76M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of RXRX is -$426.72M
What is the all-time high annual EBITDA for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual EBITDA is -$58.76M
What is Recursion Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, RXRX annual EBITDA has changed by -$119.09M (-38.71%)
What is Recursion Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of RXRX is -$151.16M
What is the all-time high quarterly EBITDA for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly EBITDA is -$17.19M
What is Recursion Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, RXRX quarterly EBITDA has changed by -$60.91M (-67.48%)
What is Recursion Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of RXRX is -$646.25M
What is the all-time high TTM EBITDA for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM EBITDA is -$17.41M
What is Recursion Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, RXRX TTM EBITDA has changed by -$281.00M (-76.93%)